Grants
Additional funding opportunities
Research Funding Opportunities
Grants Awarded for Health Sciences Research
| Title | Type | $ Amount |
Activity |
Investigator | Unit | Sponsor | Date |
|---|---|---|---|---|---|---|---|
| Technical Study: Analytical Performance Evaluation of Cobas Plus | Contract | $553,527.00 | Clinical Trial | Ryan Matika | Anesthesiology | Roche Diagnostics Operations, Inc. | 10/2020 |
| A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Infants Born to.... | Contract | $124,499.00 | Clinical Trial | Mohamed Ahmed | Pediatrics | Pfizer, Incorporated | 05/2020 |
| A Randomized, Double-Blind, Placebo-controlled, Single-ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of JK07 in Subjects with Heart Failure with Reduced Ejection Fra... | Contract | $606,162.95 | Clinical Trial | Nancy Sweitzer | Sarver Heart Center | Salubris Biotherapeutics | 01/2021 |
| Noninterventional Epigenomic Mapping of CD34+ Cells From Healthy Participants and Patients With Myelofibrosis (MF) and Polycythemia Vera (PV) | Contract | $74,529.50 | Clinical Trial | Krisstina Gowin | Cancer Center Division | Incyte Corporation | 12/2020 |
| Serum Protein-Based Indices for the Progression of Fracture Healing and Nonunion | Contract | $42,700.00 | Clinical Trial | Jason Lowe | Orthopedic Surgery | Johns Hopkins University | 02/2022 |
| Study Using Negative Pressure to Reduce Apnea (SUPRA) | Contract | $166,386.00 | Clinical Trial | Sairam Parthasarathy | Medicine | Sommetrics, Inc | 01/2022 |
| A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 with Placebo and with Tofacitinib in Combination with Conventional Synthetic DMARDs.... | Contract | $314,050.00 | Clinical Trial | Chian Kwoh | Arthritis Center-Research | IQVIA RDS Inc. | 03/2020 |
| Invasive Cardiopulmonary Exercise Testing to Phenotype Post Pulmonary Embolism Dyspnea | Contract | $99,577.00 | Clinical Trial | Michael Insel | Medicine | Bayer Healthcare Pharmaceuticals Incorporated | 11/2020 |
| Expanded Access Program Basis for the Treatment of Relapsed/Refractory Multiple Myeloma | Contract | $95,540.64 | Clinical Trial | Krisstina Gowin | Cancer Center Division | Glaxosmithkline | 06/2020 |
| COVID-19-C3PO: Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) | Contract | $1,222,500.00 | Clinical Trial | Jarrod Mosier | Dept of Emergency Medicine | University of Michigan | 08/2020 |
| A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitals Adults with COVID-19 | Contract | $178,900.00 | Clinical Trial | Bellal Joseph | Surgery | New York University | 04/2021 |
| The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (PROACTIVE) Study | Contract | $42,133.70 | Clinical Trial | Venkatesh Ariyamuthu | Medicine | Natera, Inc. | 10/2020 |
| A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic... | Contract | $297,912.00 | Clinical Trial | Rachna Shroff | Cancer Center Division | Covance, Incorporated | 05/2020 |
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial (FERMIN trial) | Contract | $5,450.00 | Clinical Trial | Nancy Sweitzer | Medicine | University of Pennsylvania | 01/2021 |
| PETAL Network International Coordinating Center for ACTIV-3 Trial Initiative | Grant | $820,500.00 | Clinical Trial | Jarrod Mosier | Dept of Emergency Medicine | Albert Einstein College of Medicine | 12/2020 |
| A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients with Brain Contusion | Contract | $96,267.00 | Clinical Trial | Bellal Joseph | Surgery | Biogen Incorporated | 03/2020 |
| RELIEVE-HF: REducing Lung CongestIon Symptoms Using the V-WavE Shunt in adVancEd Heart Failure | Contract | $621,878.00 | Clinical Trial | Nancy Sweitzer | Sarver Heart Center | V-Wave Ltd. | 11/2020 |
| PRECISE: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization | Contract | $54,987.52 | Clinical Trial | Michael Morris | COM Phx Radiology | HeartFlow, Inc. | 06/2020 |
| CREON (Pancrelipase) Therapy for Subjects with Exocrine Pancreatic Insufficiency (EPI) due to Pancreatic Cancer: A Double-Blind, Randomized, Parallel Design with 2 Dose Cohorts of Pancrelipase... | Contract | $117,787.55 | Clinical Trial | Jen-Jung Pan | COM Phx Internal Medicine | AbbVie Incorporated | 08/2020 |
| A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospital | Contract | $372,615.00 | Clinical Trial | Monica Kraft | Medicine | Janssen Research & Development, LLC | 04/2021 |
| A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma (TRYbeCA-1 - TRial of ErYaspase | Contract | $664,687.53 | Clinical Trial | Hani Babiker | Cancer Center Division | PPD Investigator Services, LLC. | 05/2020 |
| Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE) | Contract | $18,455.00 | Clinical Trial | Thomas Ardiles | COM Phx Internal Medicine | Pharmerit International | 01/2021 |
| A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction... | Contract | $105,851.40 | Clinical Trial | Aaron Wolfson | Sarver Heart Center | Cytokinetics, Incorporated | 09/2020 |
| A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering from Plaque Psoriasis Through Clinical Utility and Health Outcomes. (MATCH | Contract | $82,003.00 | Clinical Trial | Jawad Bilal | Arthritis Center-Research | Mindera Corporation | 05/2022 |
| A Phase 1/2 Study of ZN-c3 as a Single Agent in Combination with Talazoparib or Pembrolizumab in Patients with Solid Tumors | Contract | $138,409.52 | Clinical Trial | Pavani Chalasani | Cancer Center Division | K-Group Beta, Inc. | 03/2020 |